Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Skye Bioscience, Inc. Common Stock (SKYE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: SKYE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 9.49% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 43.36M USD | Price to earnings Ratio - | 1Y Target Price 16.21 |
Price to earnings Ratio - | 1Y Target Price 16.21 | ||
Volume (30-day avg) 198215 | Beta 1.71 | 52 Weeks Range 1.37 - 17.65 | Updated Date 04/2/2025 |
52 Weeks Range 1.37 - 17.65 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.73 |
Earnings Date
Report Date 2025-03-19 | When After Market | Estimate -0.285 | Actual -0.2912 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -44.56% | Return on Equity (TTM) -80.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -24595770 | Price to Sales(TTM) - |
Enterprise Value -24595770 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.56 | Shares Outstanding 30974600 | Shares Floating 15691401 |
Shares Outstanding 30974600 | Shares Floating 15691401 | ||
Percent Insiders 1.29 | Percent Institutions 82.48 |
Analyst Ratings
Rating 4.5 | Target Price 18 | Buy 3 | Strong Buy 3 |
Buy 3 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Skye Bioscience, Inc. Common Stock
Company Overview
History and Background
Skye Bioscience, Inc. (SKYE) is a biopharmaceutical company focused on developing cannabinoid-based pharmaceutical therapies. Originally founded as Emerald Bioscience, the company changed its name to Skye Bioscience, Inc. in 2021, reflecting its refined strategic focus. It's primary efforts are currently on developing a treatment for glaucoma.
Core Business Areas
- Pharmaceutical Development: Skye Bioscience focuses on the discovery, development, and commercialization of novel cannabinoid-based therapeutics for unmet medical needs. Their lead drug is targeting Glaucoma.
Leadership and Structure
Skye Bioscience's leadership team consists of experienced professionals in the pharmaceutical industry. The organizational structure includes departments for research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- SBI-100 Ophthalmic Emulsion: SBI-100 is Skye's lead drug candidate, a synthetic cannabinoid derivative intended to reduce intraocular pressure (IOP) in patients with glaucoma. It is currently in Phase 2 clinical trials. The global glaucoma market is highly competitive with many drugs and surgical treatments from companies like Novartis, Allergan (AbbVie), and Aerie Pharmaceuticals (Alcon). It's not possible to give Market Share data as this drug is in Trials and is not yet on the market. Revenue is zero.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high regulatory hurdles, and significant R&D investment. The cannabinoid-based therapeutics segment is a relatively new and rapidly evolving area.
Positioning
Skye Bioscience is positioned as a company specializing in cannabinoid-based therapies, targeting specific indications with significant unmet needs. They are a small player in a large market.
Total Addressable Market (TAM)
The glaucoma market is estimated to be around $5 billion - $6 billion annually. Skye Bioscience, if successful with SBI-100, aims to capture a portion of this market. Currently, they have no revenue.
Upturn SWOT Analysis
Strengths
- Novel cannabinoid-based therapeutic approach
- Targeting a large market with unmet needs
- Experienced leadership team
Weaknesses
- Limited financial resources
- Reliance on successful clinical trial outcomes
- Limited revenue stream
- Relatively new company
Opportunities
- Positive clinical trial results could lead to significant market value increase
- Partnerships with larger pharmaceutical companies
- Expansion into other cannabinoid-based therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles and changes
- Competition from established pharmaceutical companies
- Financing risk and market volatility
Competitors and Market Share
Key Competitors
- AGN (AbbVie)
- NVS (Novartis)
- ALC (Alcon)
Competitive Landscape
Skye Bioscience is a small player in a market dominated by larger, more established pharmaceutical companies. Its competitive advantage relies on the novelty of its cannabinoid-based approach.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is in the development stage. It primarily reflects stock price volatility associated with clinical trial events.
Future Projections: Future growth depends heavily on the successful development and commercialization of SBI-100. Analyst projections are based on assumptions about market adoption and pricing.
Recent Initiatives: Recent initiatives include advancing SBI-100 through Phase 2 clinical trials.
Summary
Skye Bioscience is a development-stage company with a promising lead drug candidate (SBI-100) targeting the glaucoma market. Its success hinges on the results of clinical trials. It faces significant competition from established pharmaceutical companies. Its small size and limited resources are weaknesses, but successful clinical trials could lead to substantial growth and partnerships.
Similar Companies
CRBP
Corbus Pharmaceuticals Holding
CRBP
Corbus Pharmaceuticals Holding
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investing in development-stage pharmaceutical companies carries significant risk. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Skye Bioscience, Inc. Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-04-02 | President, CEO, Secretary & Director Mr. Punit S. Dhillon B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://skyebioscience.com |
Full time employees 16 | Website https://skyebioscience.com | ||
Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors. The company is conducting a Phase 2 clinical trial in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.